Preclinical Toxicity and Safety of MM-129-First-in-Class BTK/PD-L1 Inhibitor as a Potential Candidate against Colon Cancer

• Principais autores: Justyna Magdalena Hermanowicz (Autor), Bartlomiej Kalaska (Autor), Krystyna Pawlak (Autor), Beata Sieklucka (Autor), Joanna Miklosz (Autor), Mariusz Mojzych (Autor), Dariusz Pawlak (Autor)
• Formato: Livro
• Publicado em: MDPI AG, 2021-08-01T00:00:00Z.
• Assuntos: article
• Acesso em linha: Connect to this object online.

MM-129 is a novel inhibitor targeting BTK/PI3K/AKT/mTOR and PD-L1, as it possesses antitumor activity against colon cancer. To evaluate the safety profile of MM-129, we conducted a toxicity study using the zebrafish and rodent model. MM-129 was also assessed for pharmacokinetics features through an...